KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $11000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization (CF) fell 96.73% to $11000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $352000.0 through Dec 2025, down 66.38% year-over-year, with the annual reading at $363000.0 for FY2025, 73.7% down from the prior year.
  • Depreciation & Amortization (CF) hit $11000.0 in Q3 2025 for Arbutus Biopharma, roughly flat from $11000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $447000.0 in Q3 2021 to a low of $11000.0 in Q2 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $332312.5 across 5 years, with a median of $355500.0 in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 7.58% in 2023 and later crashed 96.91% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $427000.0 in 2021, then dropped by 19.67% to $343000.0 in 2022, then grew by 7.58% to $369000.0 in 2023, then dropped by 8.94% to $336000.0 in 2024, then plummeted by 96.73% to $11000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ABUS at $11000.0 in Q3 2025, $11000.0 in Q2 2025, and $330000.0 in Q1 2025.